undamentalytics Newsletter
Sign in

Prelude Therapeutics Inc (PRLD) stock

Add to watchlist

Add holding +

NASDAQ: PRLD Nasdaq Biotechnology Next results ~November 11, 2026

Prelude Therapeutics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.1

Valuation models combined (2)

Base case. Range ~$1.1–$1.1. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Prelude Therapeutics Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling4 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds59 adding, 21 cuttingOf 25 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Prelude Therapeutics files

Where Prelude Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $22m. Free-cash-flow margin rose to -148.3% from -1550.4% a year earlier. Operating margin widened to -300.6% from -1928.7%. The diluted share count is up 10.9% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.68 a share, against a share price of $4.16.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Prelude Therapeutics Inc's trailing-twelve-month revenue grew 220.3% year on year, with a free-cash-flow margin of -148.3%.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 69.4% while net income grew 51.3%: a 18pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 220.3% over the last 12 months.
  • Margins widening. Operating margin is up 1628.1 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -300.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -148.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 37.0% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 10.9% in a year.
  • High sales multiple. The shares trade at 14 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.14 against an average estimate of -$0.18: beat by 24.3%
Revenue
$6m
Share reaction
+18.6% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.14

Prelude Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.0%
  • 1 week+3.8%
  • 1 month+4.6%
  • This year+32.4%
  • 1 year+141.5%
  • 5 years-79.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$22.4M
Operating margin
-300.6%
Net margin
-269.7%
EPS (TTM, diluted)
$-0.72

Growth

Revenue growth
+220.3%
Share count change
+10.9%

Cash

Free cash flow (TTM)
-$33.3M
FCF margin
-148.3%
Stock pay % of revenue
37.0%

Earnings

Last results
August 11, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Prelude Therapeutics Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Prelude Therapeutics Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.1 ~$1.0–$1.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.1 ~$1.2–$4.4 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.1 ~$1.1–$1.1 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Prelude Therapeutics Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$1.27$2.90$3.84
Market value$97m$223m$323m
+ Net debt (− = net cash)−$12m−$35m−$26m
Enterprise value$84m$188m$297m
Multiples
Price / sales 13.8x18.4x14.4x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, before the open. Analysts expect revenue of $29m and EPS of −$0.14 (range −$0.16 to −$0.13) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.57 +56% $39m +221%
Next −$0.58 −2% $36m −7%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −33.1% on 90 days ago. In the last 30 days, 1 analyst raised Prelude Therapeutics Inc's forecast and 0 cut it.

Consensus EPS forecast Prelude Therapeutics Inc, last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.85 Current fiscal year, 60 days ago: −$0.54 Current fiscal year, 30 days ago: −$0.54 Current fiscal year, 7 days ago: −$0.58 Current fiscal year, Now: −$0.57 −$0.57 Next fiscal year, 90 days ago: −$0.94 Next fiscal year, 60 days ago: −$0.75 Next fiscal year, 30 days ago: −$0.75 Next fiscal year, 7 days ago: −$0.55 Next fiscal year, Now: −$0.58 −$0.58

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.85−$0.94
60 days ago −$0.54−$0.75
30 days ago −$0.54−$0.75
7 days ago −$0.58−$0.55
Now −$0.57−$0.58

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.18 −$0.14 +24.3%
Mar 2026 −$0.27 −$0.13 +51.2%
Dec 2025 −$0.18 −$0.20 −11.1%
Sept 2025 −$0.35 −$0.26 +26.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026235
  2. Sep 2026235
  3. Aug 2026123
  4. Jul 2026123

Counts of recommendations published by analysts covering Prelude Therapeutics Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
20.1%
of tradable shares
Days to cover
10.07
at average volume
Short interest, 1 month
+41%
to October 15, 2026
Held by institutions
76%
of shares
Held by insiders
13.8%
of shares
Employees
79
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +141.5%

$1.59 on October 31, 2025 to $3.84

ThenNowEffect
Revenue (last 12 months) $7m $22m +220.3%
P/S multiple 17.2x 14.4x −16.4%
Share count 76m 84m −9.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PRLD−83%−52%−29%−70%+128%+32%
Industry peers (median)−35%−57%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PRLD17%25%42%42%58%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PRLD−87%−70%−79%−87%−70%−51%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 25, 2020: 99% from February 10, 2021 to April 8, 2025. Getting back needed a 14905% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.19 – $6.63
From 52-week high
−42.1%
vs 50-day average
−12.7%
vs 200-day average
−4.5%
Volatility (1 year)
195%
Beta vs S&P 500
1.98

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±14.6%
After a week
10 up, 2 down
typical move ±19.9%
After a month
6 up, 6 down
typical move ±25.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +18.6% −0.1% +19.0% −3.3%
May 12, 2026 −2.9% +0.4% −11.0% −14.4%
March 10, 2026 +23.3% −0.3% +11.0% +42.4%
November 12, 2025 +11.9% −1.6% +23.7% +26.7%
August 14, 2025 −4.1% −0.2% +21.3% +22.4%
May 6, 2025 −7.1% −0.4% +21.7% +19.0%
March 10, 2025 −10.2% −3.5% +2.6% −17.0%
November 6, 2024 −1.6% +3.3% −17.8% −26.0%
August 12, 2024 +21.6% +1.7% +15.1% −2.0%
May 7, 2024 −6.3% +0.1% +0.8% −1.3%
February 15, 2024 +37.0% +0.2% +17.2% +37.6%
November 1, 2023 +30.8% +3.0% +77.5% +90.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Prelude Therapeutics Inc
$0 $10M $20M $30M FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue (TTM), FY25 Q2: $7M Revenue (TTM), FY25 Q3: $10.5M Revenue (TTM), FY25 Q4: $12.1M Revenue (TTM), FY26 Q1: $16.7M Revenue (TTM), FY26 Q2: $22.4M $22.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY25 Q2 $7M
FY25 Q3 $10.5M
FY25 Q4 $12.1M
FY26 Q1 $16.7M
FY26 Q2 $22.4M
Operating margin (TTM) Prelude Therapeutics Inc
-2000% -1500% -1000% -500% 0% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Operating margin (TTM), FY25 Q2: -1928.7% Operating margin (TTM), FY25 Q3: -1152.8% Operating margin (TTM), FY25 Q4: -861.3% Operating margin (TTM), FY26 Q1: -503.2% Operating margin (TTM), FY26 Q2: -300.6% -300.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY25 Q2 -1928.7%
FY25 Q3 -1152.8%
FY25 Q4 -861.3%
FY26 Q1 -503.2%
FY26 Q2 -300.6%
FCF margin (TTM) Prelude Therapeutics Inc
-2000% -1500% -1000% -500% 0% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 FCF margin (TTM), FY25 Q2: -1550.4% FCF margin (TTM), FY25 Q3: -955.1% FCF margin (TTM), FY25 Q4: -464.3% FCF margin (TTM), FY26 Q1: -261.8% FCF margin (TTM), FY26 Q2: -148.3% -148.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY25 Q2 -1550.4%
FY25 Q3 -955.1%
FY25 Q4 -464.3%
FY26 Q1 -261.8%
FY26 Q2 -148.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 7 12 22
EBITDA −138 −103 −66
Operating income −140 −105 −67
Net income −127 −99 −60
Diluted EPS −$1.68 −$1.29 −$0.72
Growth (year on year)
Revenue — +73.4% +220.3%
Margins
EBITDA margin <−999% −847.2% −293.5%
Operating margin <−999% −861.3% −300.6%
Net margin <−999% −819.6% −269.7%
Free-cash-flow margin <−999% −464.3% −148.3%
Cash flow
Cash from operations −103 −56 −33
Capital spending 1 0 0
Free cash flow −104 −56 −33
Stock-based pay 21 12 8
Free cash flow after stock pay −125 −68 −42
Balance sheet
Cash 12 35 26
Total debt 0 0 0
Net debt (negative = net cash) −12 −35 −26
Diluted shares 76m 77m 84m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $189m
Short-term assets $155mLonger-term assets $34m
What it owes, and who funded it · $189m
Short-term liabilities $38mLonger-term liabilities $18mShareholders' equity $134m
  • Short-term assets cover short-term liabilities $155m of assets due within a year against $38m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $155m short-term assets against $18m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Prelude Therapeutics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+10.9%
year over year
R&D spending
309.6%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated PRLD JANX CRSP ABEO SCYX CELU Median
Revenue, last 12 months $22m $24m $25m $26m $19m $19m $55m
Revenue growth, last 12 months 220.3% >999% −34.3% −87.7% 489.8% −58.1% 12.7%
Revenue growth, 3-year average — 45.7% −47.1% 212.0% −47.9% 7.2% 13.7%
Revenue growth, latest quarter 41.0% >999% >999% >999% −82.8% −5.3% 10.2%
Gross margin — — — 67.1% 26.0% 19.2% 82.9%
Operating margin −300.6% −598.1% <−999% −327.6% −117.6% −264.3% −191.1%
Operating margin, 3-year average — <−999% <−999% <−999% −592.1% −204.2% −363.5%
Net margin −269.7% −427.5% <−999% −246.4% −53.3% −245.7% −172.8%
Cash from operations / revenue −148.3% −171.9% <−999% −299.5% −69.3% −47.8% −162.3%
Free-cash-flow margin −148.3% −174.7% <−999% −319.5% −69.3% −80.1% −156.7%
Free-cash-flow margin, 3-year average — <−999% −793.9% <−999% −304.8% −50.3% −310.0%
Stock pay / revenue 37.0% 153.7% 276.8% 45.4% 12.3% 66.5% 20.7%
Change in share count 10.9% 6.2% 10.0% 36.6% 1.9% 24.7% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$264M
Institutions reporting
75
Shares held vs prior quarter
▲ 61.2%
Positions opened / closed
34 / 13

Top buyers and sellers, Q2 2026: 59 institutions bought and 21 sold ; the biggest buyer was RA Capital Management, L.P (+6.5M shares) and the biggest seller Ecor1 Capital, LLC (−947K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Orbimed Advisors LLC $73.2M 13.7M 27.7% ▲ 25.8%
Baker Bros. Advisors LP $54M 10.1M 20.4% 0.0%
RA Capital Management, L.P. $34.5M 6.5M 13.1% New
Soleus Capital Management, L.P. $18M 3.4M 6.8% New
Kynam Capital Management, LP $12.9M 2.4M 4.9% ▲ 51.6%
Vanguard Capital Management LLC $10.7M 2.0M 4.1% ▲ 63.3%
Blackrock, Inc. $9.6M 1.8M 3.6% ▲ 458.4%
Sphera Funds Management Ltd. $5.4M 1.0M 2.1% ▲ 82.7%
Two Sigma Investments, LP $5.3M 993K 2.0% ▲ 7.6%
ADAR1 Capital Management, LLC $4.8M 901K 1.8% ▲ 489.5%
Millennium Management LLC $4.5M 845K 1.7% ▲ 120.8%
Geode Capital Management, LLC $4.5M 842K 1.7% ▲ 178.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Prelude Therapeutics Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $25M 4 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $25M net buying
Insider Date Trade Shares Price Value
Orbimed Genesis Gp Llc Director April 21, 2026 Buy 1,126,126 $4.44 $5M
Orbimed Genesis Gp Llc Director April 21, 2026 Buy 1,689,189 $4.44 $7.5M
Bonita David P Director April 21, 2026 Buy 1,126,126 $4.44 $5M
Bonita David P Director April 21, 2026 Buy 1,689,189 $4.44 $7.5M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 10, 2026
  • November 12, 2025
  • August 14, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Prelude Therapeutics Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Prelude Therapeutics Inc in brief

What does Prelude Therapeutics Inc do?
Prelude Therapeutics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Prelude Therapeutics Inc's stock ticker?
Prelude Therapeutics Inc trades under the ticker PRLD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Prelude Therapeutics Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Prelude Therapeutics Inc reported revenue of $22.4M, 220.3% higher than a year earlier, according to its SEC filings.
What is Prelude Therapeutics Inc's free cash flow?
Prelude Therapeutics Inc's free-cash-flow margin is -148.3% of revenue over the trailing twelve months.
Who are Prelude Therapeutics Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Orbimed Advisors LLC, Baker Bros. Advisors LP and RA Capital Management, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Prelude Therapeutics Inc's market cap?
On November 2, 2026, Prelude Therapeutics Inc's market capitalisation was about $323M and net debt of -$26.3M. Market figures come from third-party market data and may be delayed.
Who are Prelude Therapeutics Inc's competitors?
In our Biotechnology peer group, the companies closest to Prelude Therapeutics Inc are Janux Therapeutics, Inc., Crispr Therapeutics AG, Abeona Therapeutics Inc., Scynexis Inc and Celularity Inc. The side-by-side comparison below sets their revenue, margins and growth against Prelude Therapeutics Inc's.
Are insiders buying or selling Prelude Therapeutics Inc stock?
Over the last 12 months, Prelude Therapeutics Inc's directors and officers reported 4 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Prelude Therapeutics Inc's next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Prelude Therapeutics Inc announces its own schedule.